Reporter brief
Metformin pilot RCT tested feasibility of assessing effects on cellular aging and physical performance.
What happened
This pilot and feasibility RCT examined whether chronic metformin administration could reduce aging-related biochemical parameters and improve physical performance in elderly participants, as measured by short physical performance battery testing. The authors framed the study as testing potential benefits for cellular longevity and aging markers, but specific outcomes, sample size, and effect sizes were not reported in the provided abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Elderly
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Nov 17, 2022
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.